

# Marathon Patent Group Announces Second Quarter Financial Results

## Conference Call Scheduled Today at 4:30 p.m. Eastern Time

LOS ANGELES, CA -- (Marketwired) -- 08/15/16 -- Marathon Patent Group, Inc. (NASDAQ: MARA) ("Marathon" or "Company"), an IP licensing and commercialization company, today announced its operating results for the quarter ended June 30, 2016, as published in its Quarterly Report on Form 10-Q filed today with the Securities and Exchange Commission.

### Operating Results for the Quarter Ended June 30, 2016 and Subsequent Events

- Record Q2 revenue of \$34.3 million for the three months ended June 30, 2016
- Record Q2 non-GAAP net income of \$16.5 million, compared to non-GAAP net loss of \$4.5 million for Q2 2015
- Record Q2 GAAP net profit of \$7.9 million or \$0.53 per basic share compared to a GAAP net loss of \$4.5 million or \$(0.32) per basic share for Q2 2015
- Record six months revenue of \$36.4 million. First half record operating income of \$9.1 million
- Debt reduction of \$7.4M
- Other operating expenses in Q2 2016 of approximately \$4.9 million, a 20% decrease as compared to operating expenses of \$6.1 million in Q2 2015
- Named Erich Spangenberg as Director of Acquisitions, Licensing, and Strategy
  primarily focusing on acquisitions, licensing, alliances and strategy for Marathon, with
  an emphasis on Marathon's expansion into Asia and Europe
- Added Dr. David Liu to the management team with over 20 years of deep domain experience in the areas of memory and semiconductor technology
- Entered into a strategic relationship with a large fund and a Fortune Global 50 company on August 11, 2016 to commercialize and monetize 10,000+ patents in a particular industry vertical
- Entered into agreement with Siemens AG acquiring 307 patents, many deemed Standard Essential Patents
- Secured a lead investor for 3D Nanocolor

Doug Croxall, Chief Executive Officer of Marathon, stated, "We are clearly pleased with year to date record financial results that we announced today, including improving our balance sheet and successfully retiring a large portion of debt."

Croxall concluded, "As discussed on our previous earnings call, we are refocusing our revenue generation on licenses that provide a recurring revenue feature. The recurring revenue may take the form of fixed quarterly or annual payments by licensees to Marathon and should help investors better model future revenue potential."

### Conference Call

Marathon will host a corresponding conference call to discuss the results with Chief Executive Officer Doug Croxall and Chief Financial Officer Frank Knuettel II on Monday, August 15, 2016 at 4:30 PM ET/1:30 PM PT. To participate in the conference call, investors from the U.S. and Canada should dial (877) 407-4018 ten minutes prior to the scheduled start time. International calls should dial (201) 689-8471.

In addition, the call will be broadcast live over the Internet and can be accessed through the Investor Relations section of the Company's website at <a href="www.marathonpg.com">www.marathonpg.com</a>. The broadcast will be archived online upon completion of the conference call. A telephonic replay of the conference call will also be available until 11:59 p.m. ET on Monday, August 29, 2016 by dialing (877) 870-5176 in the U.S. and Canada and (858) 384-5517 internationally and entering the pin number: 13643010.

### About Marathon Patent Group

Marathon is an IP licensing and commercialization company. The Company acquires and manages IP rights from a variety of sources, including large and small corporations, universities and other IP owners. Marathon has a global focus on IP acquisition and management. The Company's commercialization division is focused on the full commercialization lifecycle which includes discovering opportunities, performing due diligence, providing capital, managing development, protecting and developing IP, assisting in execution of the business plan, and realizing shareholder value. To learn more about Marathon Patent Group, visit <a href="https://www.marathonpg.com">www.marathonpg.com</a>.

#### Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or

## otherwise, except as required by law.

# MARATHON PATENT GROUP, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

		June 30, 2016	D	ecember 31, 2015
ASSETS		(unaudited)		2013
Current assets:		(unaudited)		
Cash	\$	7,158,779	\$	2,555,151
Accounts receivable - net of allowance for bad debt of \$387,976 and \$375,750	*	.,,	Ψ	_,000,101
for June 30, 2016 and December 31, 2015		128,337		136,842
Bonds posted with courts		2,383,069		1,748,311
Prepaid expenses and other current assets, net of discounts of \$3,103 for June 30, 2016 and \$3,414 for December 31, 2015		177,745		338,598
Total current assets		9,847,930		4,778,902
Other assets:				
Property and equipment, net of accumulated depreciation of \$87,662 and \$67,052 for June 30, 2016 and December 31, 2015		46,977		61,297
Intangible assets, net of accumulated amortization of \$18,013,247 and \$15,557,353 for June 30, 2016 and December 31, 2015		23,488,453		25,457,639
Deferred tax assets		8,893,421		12,437,741
Other non current assets, net of discounts of \$3,279 and \$4,831 for June 30,				
2016 and December 31, 2015		204,721		9,169
Goodwill		4,453,945		4,482,845
Total other assets		37,087,517		42,448,691
Total Assets	\$	46,935,447	\$	47,227,593
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:				
Accounts payable and accrued expenses	\$	6,142,186	\$	6,534,825
Clouding IP earn out - current portion		-		33,646
Notes payable, net of discounts of \$788,320 and \$730,945 for June 30, 2016 and December 31, 2015		8,793,806		10,383,177
		14,935,992		16,951,648
Long-term liabilities				
Notes payable, net of discount of \$1,016,198 and \$1,425,167 for June 30, 2016 and December 31, 2015		9,027,798		12,223,884
Clouding IP earn out		3,147,054		3,281,238
Deferred tax liability		789,690		1,044,997
Revenue share liability		1,000,000		1,000,000
Other long term liability	_	47,549		50,084
Total long-term liabilities		14,012,091		17,600,203
Total liabilities		28,948,083		34,551,851
Stockholders' Equity:				
Preferred stock Series B, \$.0001 par value, 50,000,000 shares authorized: 782,004 and 782,004 issued and outstanding at June 30, 2016 and December 31, 2015		78		78
Common stock, \$.0001 par value; 200,000,000 shares authorized; 15,047,141		. •		. •
and 14,867,141 at June 30, 2016 and December 31, 2015		1,505		1,487
Additional paid-in capital		44,422,717		43,217,513
Accumulated other comprehensive income (loss)		(1,168,556)		(1,265,812)
Accumulated deficit		(25,264,658		(29,277,524)
Total Marathon Patent Group, Inc. stockholders' equity		17,991,086		12,675,742
Noncontrolling Interest		(3,722)		

The accompanying notes are an integral part to these unaudited consolidated financial statements.

# MARATHON PATENT GROUP, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

	J	For The hree Months Ended une 30, 2016	_	For The Three Months Ended June 30, 2015	_	For The Six Months Ended June 30, 2016		For The Six Months Ended June 30, 2015
B		(unaudited)	•	(unaudited)	•	(unaudited)	Φ.	(unaudited)
Revenues	\$	34,349,762	\$	1,368,986	\$	36,409,438	\$	5,462,855
Expenses								
Cost of revenues		15,467,763		3,860,210		18,107,740		8,188,375
Amortization of patents and website		1,961,411		3,029,000		3,987,310		5,627,461
Compensation and related taxes		1,120,924		1,087,058		2,154,270		2,668,132
Consulting fees		364,836		329,081		645,612		1,225,624
Professional fees		498,212		578,920		903,705		1,348,535
General and administrative		223,130		284,976		428,513		504,457
Goodwill impairment		83,000		-		83,000		-
Patent impairment		620,696	_	766,498	_	993,890		766,498
Total operating expenses		20,339,972	_	9,935,743	_	27,304,040		20,329,082
Operating income (loss) from continuing operations		14,009,790	_	(8,566,757	) _	9,105,398		(14,866,227)
Other income (expenses)								
Other income (expense)		(17,745	)	7,439		(31,532	)	7,439
Foreign exchange gain (loss)		(69,201	)	1,899		(62,223	)	(37,503)
Change in fair value adjustment of Clouding IP earn out		169,172		2,304,301		167,830		2,304,301
Interest income		931		-		1,862		2
Interest expense		(844,407	)	(1,577,083	)	(1,851,256	)	(2,508,623)
Total other income (expenses)		(761,250	) _	736,556		(1,775,319	)	(234,384)
Income (loss) before income tax benefit (expense)		13,248,540		(7,830,201	)	7,330,079		(15,100,611 )
Income tax benefit (expense)		(5,345,983	)	3,327,505		(3,320,935	)	5,816,344
Net income (loss)		7,902,557	′ —	(4,502,696	)	4,009,144		(9,284,267)
Net (income) loss attributable to noncontrolling interests		3,722	_		_	3,722		<u>-</u>
Net income (loss) attrributable to Marathon Patent Group, Inc. common shareholders	\$	7,906,279	\$	(4,502,696	) <u>\$</u>	4,012,866	\$	(9,284,267)
Income (loss) per common share:								
Basic	\$	0.53	\$	(0.32	) \$	0.27	\$	(0.67)
Fully Diluted	\$	0.49	\$	(0.32	=	0.25	\$	(0.67)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:	==		Ė		′ <u>≐</u>		==	(
Basic		14,994,697		13,998,563		14,980,919		13,937,872
Fully Diluted	==	16,031,564	=	13,998,563	=	16,017,786	_	13,937,872
Other income (loss)  Foreign currency translation adjustments	\$	(150,171	) \$	319,905	\$	97,256	\$	(630,334)
			_					

The accompanying notes are an integral part to these unaudited consolidated financial statements.

### CONSOLIDATED STATEMENTS OF CASH FLOWS

	For The		For The		
		Ionths Ended	Six Months Ended June 30, 2015		
	-	ne 30, 2016			
Cash flows from operating activities:	-	ınaudited)		unaudited)	
	\$	4,009,144	\$	(9,284,267)	
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:					
Depreciation		2,710		3,758	
Amortization of patents and website		3,987,310		5,627,461	
Deferred tax asset		3,547,856		(5,307,139)	
Deferred tax liability		(275,490)		(509,207)	
Impairment of intangible assets		993,890		766,498	
Impairment of goodwill		83,000		-	
Stock based compensation		1,062,200		1,413,724	
Stock issued for services		136,000		750,334	
Non-cash interest, discount, and financing costs		664,182		1,625,322	
Change in fair value of Clouding earnout		(167,830)		(2,304,301)	
Allowance for doubtful accounts		12,226		-	
Other non-cash adjustments		(104,899)		14,980	
Changes in operating assets and liabilities					
Bonds posted with courts		(518,455)		-	
Accounts receivable		(2,718)		(487,328)	
Prepaid expenses and other assets		165,301		51,455	
Accounts payable and accrued expenses		(469,660)		2,046,662	
Net cash provided by (used in) operating activities		13,124,767		(5,592,048)	
Cash flows from investing activities:					
Acquisition of patents		(1,150,000)		-	
Purchase of property, equipment, and other intangible assets		(6,291)		(20,668)	
Net cash provided by (used in) investing activities		(1,156,291)		(20,668)	
Cash flows from financing activities:					
Payment on note payable in connection with the acquisition of Medtech and Orthophoenix		(2,953,779)		(4,200,000)	
Payment on note payable in connection with the acquisition of Orthophoenix				(5,000,000)	
Payment on note payable in connection with the acquisition of Sarif		-		(276,250)	
Payment on note payable in connection with the acquisition of IP Liquidity		_		(1,109,375)	
Payment on note payable in connection with the acquisition of Dynamic Advances		_		(2,624,375)	
Payment on MdR Escrow TLI		_		(50,000)	
Cash received upon issuance of notes payable (net of issuance costs)		_		19,600,000	
Payment on Fortress note payable		(3,973,854)		-	
Cash received upon exercise of warrants		(0,070,007)		18,751	
Repayment of convertible notes payable		_		(5,050,000)	
Payment on note payable		(437,070)		705,093	
Net cash provided by (used in) financing activities		(7,364,703)		2,013,844	
Effect of exchange rate changes on cash		(145)		3,545	
Net increase (decrease) in cash		4,603,628		(3,595,327)	
Cash at beginning of period		2,555,151		5,082,569	
Cash at end of period	<u>\$</u>	7,158,779	<u>\$</u>	1,487,242	
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for:					
	\$	1,187,074	\$	805,106	

Taxes paid	\$ 27,682	\$ 14,662
Loan fees	\$ -	\$ 400,000
Cash invested in 3DNano	\$ 115,000	\$ -
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:		
Common stock issued in conjunction with note payable	\$ 	\$ 1,000,000
Warrant issued in conjunction with note payable	\$ _	\$ 318,679
Revenue share liability incurred in conjunction with note payable	\$ _	\$ 1,000,000
Convertible debt warrant repricing	\$ 6,425	\$ 
Note payable issuance in conjunction with the acquisition of Munitech patents	\$ 1,750,000	\$ -
Non-cash interest increase in debt assumed in the Orthophoenix acquisition	\$ -	\$ 750,000
Note payable issuance in conjunction with the acquisition of BATO patents	\$ _	\$ 10,000,000

The accompanying notes are an integral part to these unaudited consolidated financial statements.

	Non-GAAP Reconciliation								
		For the Three Months Ended June 30, 2016		For the Three Months Ended June 30, 2015		For the Six Months Ended June 30, 2016		For the Six Months Ended June 30, 2015	
Net income (loss)	\$	7,906,279	\$	(4,502,696)	\$	4,012,866	\$	(9,284,267)	
Non-GAAP									
Amortization of intangible assets		1,961,411		3,029,000		3,987,310		5,627,461	
Equity-based compensation		647,764		750,968		1,192,797		2,210,051	
Impairment of intellectual property		703,696		766,498		1,076,890		766,498	
Change in earn out liability		(169,172)		(2,304,301)		(167,830)		(2,304,301)	
Non-cash interest expense		58,492		1,089,798		664,182		1,703,517	
Deferred tax (benefit) / tax expense		5,345,983		(3,327,505)		3,320,935		(5,816,344)	
Other		13,284		1,852		14,936		3,758	
Non-GAAP net income (loss)	\$	16,467,737	\$	(4,496,386)	\$	14,102,086	\$	(7,093,627)	
Weighted average common shares outstanding - basic		14,994,697		13,998,563		14,980,919		13,937,872	
Weighted average common shares outstanding - diluted		16,031,564		13,998,563		16,017,786		13,937,872	
Non-GAAP net income (loss) per common share - basic	\$	1.10	\$	(0.32)	\$	0.94	\$	(0.51)	
Non-GAAP net income (loss) per common share - diluted	\$	1.03	\$	(0.32)	\$	0.88	\$	(0.51)	

## **CONTACT INFORMATION**

Marathon Patent Group Jason Assad 678-570-6791 Email Contact

Source: Marathon Patent Group